<?xml version="1.0" encoding="UTF-8"?>


<article dtd-version="1.0" article-type="research-article">
  <front>
      <journal-meta>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">intejhealeconman</journal-id>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">j50020182</journal-id>
         <journal-title-group xmlns:xlink="http://www.w3.org/1999/xlink">
            <journal-title>International Journal of Health Economics and Management</journal-title>
         </journal-title-group>
      
         <publisher>
            <publisher-name>Springer</publisher-name>
         </publisher>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="ppub">21999023</issn>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="epub">21999031</issn>
         <custom-meta-group xmlns:xlink="http://www.w3.org/1999/xlink"/>
      </journal-meta>
      <article-meta xmlns:xlink="http://www.w3.org/1999/xlink">
         <volume xmlns:mml="http://www.w3.org/1998/Math/MathML"
                 xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">15</volume>
         <issue xmlns:mml="http://www.w3.org/1998/Math/MathML"
                xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">3</issue>
         <issue-id>i40228030</issue-id>
         <article-id pub-id-type="doi">10.2307/45271449</article-id>
         <article-categories>
            <subj-group>
               <subject>RESEARCH ARTICLE</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Reference pricing in the presence of pseudo-generics</article-title>
         </title-group>
         <contrib-group>
            <contrib>
               <string-name>
                  <given-names>Ricardo</given-names>
                  <surname>Gonçalves</surname>
               </string-name>
            </contrib>
            <contrib>
               <string-name>
                  <given-names>Vasco</given-names>
                  <surname>Rodrigues</surname>
               </string-name>
            </contrib>
            <contrib>
               <string-name>
                  <given-names>Hélder</given-names>
                  <surname>Vasconcelos</surname>
               </string-name>
            </contrib>
         </contrib-group>
         <pub-date pub-type="ppub">
            <day>1</day>
            <month>9</month>
            <year>2015</year>
         </pub-date>
         <fpage>281</fpage>
         <lpage>305</lpage>
      
      
      
         <self-uri xlink:href="https://www.jstor.org/stable/45271449"/>
      
      
         <abstract>
            <p>This paper looks at producers of branded and generic Pharmaceuticals' pricing decisions under two possible reimbursement schemes—reference pricing and fixed percentage reimbursement—and under two settings—one where the branded producer only sells the (off-patent) branded pharmaceutical and another where, in addition, it may also sell its own generic version, a so called pseudo-generic. We find different pricing responses from firms under the two reimbursement schemes and across the two settings analysed (with or without a pseudo-generic), and show that pseudo-generics may have an anticompetitive effect. Our results have important policy implications such as showing that the presence of pseudogenerics reinforces reference pricing's advantages over alternative reimbursement schemes.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
  </front>
  <back>
    
      <fn-group xmlns:xlink="http://www.w3.org/1999/xlink">
        <title>[Footnotes]</title>
        <fn id="d394e168a1310">
            <label>1</label>
          
            <p>
               <mixed-citation id="d394e175" publication-type="other">
Hollis 2003;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e181" publication-type="other">
Kong and Seldon 2004;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e187" publication-type="other">
Reiffen and Ward 2007;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e194" publication-type="other">
Granier and Trinquard 2012</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e200" publication-type="other">
Hollis 2002, 2003;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e206" publication-type="other">
Hollis and Liang 2007;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e212" publication-type="other">
Aitken et al. 2013;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e218" publication-type="other">
Grootendorst 2007;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e224" publication-type="other">
Berndt et al.
2007a, b;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e234" publication-type="other">
Appelt 2010);</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e240" publication-type="other">
Kamień and Zang (1999)</mixed-citation>
            </p>
        </fn>
        <fn id="d394e247a1310">
            <label>2</label>
          
            <p>
               <mixed-citation id="d394e254" publication-type="other">
Ellis and
McGuire (1986);</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e263" publication-type="other">
Rickman and McGuire (1999)</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e269" publication-type="other">
Bardey et al. (2012).</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e276" publication-type="other">
Mossialos et al. (2004).</mixed-citation>
            </p>
        </fn>
        <fn id="d394e283a1310">
            <label>3</label>
          
            <p>
               <mixed-citation id="d394e290" publication-type="other">
Miraldo
2009).</mixed-citation>
            </p>
        </fn>
        <fn id="d394e300a1310">
            <label>4</label>
          
            <p>
               <mixed-citation id="d394e307" publication-type="other">
López-Casasnovas and Puig-Junoy (2000).</mixed-citation>
            </p>
        </fn>
        <fn id="d394e315a1310">
            <label>8</label>
          
            <p>
               <mixed-citation id="d394e322" publication-type="other">
Hotelling (1929)</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d394e328" publication-type="other">
Brekke et al. (2007)</mixed-citation>
            </p>
        </fn>
        <fn id="d394e335a1310">
            <label>17</label>
          
            <p>
               <mixed-citation id="d394e342" publication-type="other">
Rodrigues et al. (2014).</mixed-citation>
            </p>
        </fn>
        <fn id="d394e349a1310">
            <label>22</label>
          
            <p>
               <mixed-citation id="d394e356" publication-type="other">
Rodrigues et al. (2014).</mixed-citation>
            </p>
        </fn>
        <fn id="d394e363a1310">
            <label>25</label>
          
            <p>
               <mixed-citation id="d394e370" publication-type="other">
Rodrigues et al. (2014),</mixed-citation>
            </p>
        </fn>
      </fn-group>
    
    
      <ref-list>
        <title>References</title>
        <ref id="d394e386a1310">
          
            <mixed-citation id="d394e390" publication-type="other">
Aitken, M., Berndt, E., Bosworth, B., Cockbum, I., Frank, R., Kleinrock, M., &amp; Shapiro, B. (2013). The
regulation of prescription drug competition and market responses: Patterns in prices and sales following
loss of exclusivity. NBER Working Paper 19487.</mixed-citation>
        </ref>
        <ref id="d394e403a1310">
          
            <mixed-citation id="d394e407" publication-type="other">
Appelt, S. (2010). Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent
Generic Entry. Discussion Paper No. 2010-23, University of Munich.</mixed-citation>
        </ref>
        <ref id="d394e417a1310">
          
            <mixed-citation id="d394e421" publication-type="other">
Bardey, D., Canta, C., &amp; Lozachmeur, J.-M. (2012). The regulation of health care providers' payments when
horizontal and vertical differentiation matter. Journal of Health Economics, 31(5), 691-704.</mixed-citation>
        </ref>
        <ref id="d394e431a1310">
          
            <mixed-citation id="d394e435" publication-type="other">
Berndt, E., Mortimer, R., Bhattachaijya, A., Parece, A., &amp; Tuttle, E. (2007a). Authorized generic drugs, price
competition, and consumers welfare. Health Affairs, 26(3), 790-799.</mixed-citation>
        </ref>
        <ref id="d394e446a1310">
          
            <mixed-citation id="d394e450" publication-type="other">
Berndt, E., Mortimer, R., &amp; Parece., A. (2007b). Do Authonzed Generic Drugs Deter Paragraph IV Certifica-
tions? Recent Evidence, Working Paper. Cambridge: Analysis Group.</mixed-citation>
        </ref>
        <ref id="d394e460a1310">
          
            <mixed-citation id="d394e464" publication-type="other">
Brekke, K., Königbauer, I., &amp; Straume, O. (2007). Reference pricing of pharmaceuticals. Journal of Health
Economics, 26(3), 613-642.</mixed-citation>
        </ref>
        <ref id="d394e474a1310">
          
            <mixed-citation id="d394e478" publication-type="other">
Ellis, R., &amp; McGuire, T. (1986). Provider behavior under prospective reimbursement. Journal of Health
Economics, 5(2), 1 29-151.</mixed-citation>
        </ref>
        <ref id="d394e488a1310">
          
            <mixed-citation id="d394e492" publication-type="other">
European Commission (2009). Pharmaceutical Sector Inquiry -final report, retrieved from http://ec.europa.
eu/competition/sectors/pharmaceuticals/inquiry/.</mixed-citation>
        </ref>
        <ref id="d394e502a1310">
          
            <mixed-citation id="d394e506" publication-type="other">
Ferrándiz, J. (1999). The impact of generic goods in the pharmaceutical industry. Health Economics, 8(7),
599-612.</mixed-citation>
        </ref>
        <ref id="d394e516a1310">
          
            <mixed-citation id="d394e520" publication-type="other">
Garattini, L., Cornago, D., &amp; De Compadri, P. (2007). Pricing and reimbursement of in-patent drugs in seven
European countries: A comparative analysis. Health Policy, 82(3), 330-339.</mixed-citation>
        </ref>
        <ref id="d394e531a1310">
          
            <mixed-citation id="d394e535" publication-type="other">
Granier, L., &amp; Trinquard, S. (2012). Prédation in off-patent drug markets. Applied Economics, 44(17), 2171-
2186.</mixed-citation>
        </ref>
        <ref id="d394e545a1310">
          
            <mixed-citation id="d394e549" publication-type="other">
Grootendorst, P. (2007). Effects of 'authorized generics' on Canadian drug prices, SEDAP Research Paper no.
201, McMaster University.</mixed-citation>
        </ref>
        <ref id="d394e559a1310">
          
            <mixed-citation id="d394e563" publication-type="other">
Hollis, A. (2002). The importance of being first: evidence from Canadian generic pharmaceuticals. Health
Economics, 11(8), 723-734.</mixed-citation>
        </ref>
        <ref id="d394e573a1310">
          
            <mixed-citation id="d394e577" publication-type="other">
Hollis, A. (2003). The anti-competitive effects of brand-controlled 'pseudo-generics' in the Canadian phar-
maceutical market. Canadian Public Policy, 29(1), 21-32.</mixed-citation>
        </ref>
        <ref id="d394e587a1310">
          
            <mixed-citation id="d394e591" publication-type="other">
Hollis, A. (2005). How do brands "Own Generics affect pharmaceutical prices? Review of Industrial Orga-
nization, 27(4), 329-350.</mixed-citation>
        </ref>
        <ref id="d394e601a1310">
          
            <mixed-citation id="d394e605" publication-type="other">
Hollis, A., &amp; Liang, B. (2007). An assessment of the effect of authorized generics on consumer prices. Journal
ofBiolaw &amp; Business, 10(1), 10-18.</mixed-citation>
        </ref>
        <ref id="d394e616a1310">
          
            <mixed-citation id="d394e620" publication-type="other">
Hotelling, H. (1929). Stability in competition. Economic Journal, 59(153), 41-57.</mixed-citation>
        </ref>
        <ref id="d394e627a1310">
          
            <mixed-citation id="d394e631" publication-type="other">
Kamien, M., &amp; Zang, I. (1999). Virtual patent extension by cannibalization. Southern Economic Journal,
66(1), 117-131.</mixed-citation>
        </ref>
        <ref id="d394e641a1310">
          
            <mixed-citation id="d394e645" publication-type="other">
Kong, Y., &amp; Seldon, J. (2004). Pseudo-generic products and barriers to entry in pharmaceutical markets. Review
of Industrial Organization, 25(1), 71-86.</mixed-citation>
        </ref>
        <ref id="d394e655a1310">
          
            <mixed-citation id="d394e659" publication-type="other">
Löfgren, H. (2009). Generic medicines in Australia: Business dynamics and recent policy reform. Southern
Med Review, 2(2), 24-28.</mixed-citation>
        </ref>
        <ref id="d394e669a1310">
          
            <mixed-citation id="d394e673" publication-type="other">
López-Casasnovas, &amp; Puig-Junoy, J. (2000). Review of the literature on reference pricing. Health Policy,
54(2), 87-123.</mixed-citation>
        </ref>
        <ref id="d394e683a1310">
          
            <mixed-citation id="d394e687" publication-type="other">
Miraldo, M. (2009). Reference pricing and firms' pricing strategies. Journal of Health Economics, 28(1),
176-197.</mixed-citation>
        </ref>
        <ref id="d394e698a1310">
          
            <mixed-citation id="d394e702" publication-type="other">
Mossialos, E., Mrázek, M., &amp; Walley, T. (2004). Regulating pharmaceuticals in Europe: Striving for efficiency,
equity, and quality. Maidenhead: Open University Press.</mixed-citation>
        </ref>
        <ref id="d394e712a1310">
          
            <mixed-citation id="d394e716" publication-type="other">
Reiffen, D., &amp; Ward, M. (2007). Branded generics' as a strategy to limit cannibalization of pharmaceutical
markets. Managerial and Decision Economics, 28(4-5), 251-265.</mixed-citation>
        </ref>
        <ref id="d394e726a1310">
          
            <mixed-citation id="d394e730" publication-type="other">
Rickman, N., &amp; McGuire, A. (1999). Regulating providers' reimbursement in a mixed market for health care.
Scottish Journal of Political Economy, 46(1), 53-71.</mixed-citation>
        </ref>
        <ref id="d394e740a1310">
          
            <mixed-citation id="d394e744" publication-type="other">
Rodrigues, V., Gonçalves, R., &amp; Vasconcelos, H. (2014). Anticompetitive impact of pseudo-generics. Journal
of Industry, Competition and Trade, 14(1), 83-98.</mixed-citation>
        </ref>
        <ref id="d394e754a1310">
          
            <mixed-citation id="d394e758" publication-type="other">
Tele, P., &amp; Groot, W. (2009). Cost containment measures for pharmaceuticals expenditure in the EU countries:
A comparative analysis. The Open Health Services and Policy Journal, 2, 71-83.</mixed-citation>
        </ref>
      </ref-list>
    
  </back>
</article>


